WHO FCTC Announces Opening of COP10

2Firsts Events by 2FIRSTS.ai
Feb.06.2024
WHO FCTC Announces Opening of COP10
The World Health Organization Framework Convention on Tobacco Control (WHO FCTC) announces the opening of its 10th Conference of Parties (COP10).

The 10th Conference of the Parties (COP10) of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) was officially announced on the organization's website on February 5th.

 

The 183 signatories of this convention, representing over 90% of the global population, are collectively working to strengthen and promote tobacco control. Despite the ongoing global population growth in the first two decades of this century, the smoking rate among adults has dropped from nearly 33% to 22%.

 

Dr. Adriana Blanco Marquizo, Director of the Secretariat of the WHO Framework Convention on Tobacco Control, welcomed the participants and raised concerns about the growing prevalence of emerging nicotine and tobacco products.

 

She pointed out that these products "have become a concerning issue, with young people rapidly increasing their usage. One of the reasons is the tobacco industry's misleading information, portraying these products as substitutes for real tobacco control measures. The tobacco industry is once again trying to gain a foothold in addressing the epidemic problem it created and continues to perpetuate.

 

She further urged everyone to be vigilant about the relentless interference of the tobacco industry worldwide, highlighting that "the tobacco industry is attempting to undermine not just COP10, but the efforts of every Conference of the Parties.

 

The Conference of the Parties (COP) is the decision-making body of the World Health Organization Framework Convention on Tobacco Control, comprising of all the treaty's signatories. It regularly reviews the implementation of the convention and makes necessary decisions to promote its effective implementation.

 

The conference will consider a range of actions to guide future work on addressing the global tobacco epidemic, which annually claims the lives of 8.7 million people worldwide, in line with the World Health Organization's Framework Convention on Tobacco Control.

 

The discussion topics at COP10 include:

 

  • Implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control (Regulation of Tobacco Product Ingredients and Disclosure): Report Presented by the Bureau, Expert Group, and WHO  
  • Tobacco Advertising, Promotion, and Sponsorship: Depictions of Tobacco in Entertainment Media: Report Presented by the Working Group  
  • NTPs and Emerging Tobacco Products  
  • Future Tobacco Control Measures (Related to Article 2.1 of the WHO Framework Convention on Tobacco Control)  
  • Implementation of Article 19 of the WHO Framework Convention on Tobacco Control: Responsibilities  
  • Improving the Reporting System of the WHO Framework Convention on Tobacco Control  
  • Implementation Review Mechanism  
  • Contribution of the WHO Framework Convention on Tobacco Control to the Promotion and Realization of Human Rights  
  • WHO Framework Convention on Tobacco Control Investment Fund

Furthermore, discussions on the tobacco control investment fund and the upcoming COP10, scheduled to run from today until Saturday, February 10th, are expected. Following that, the Third Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products (MOP3) is set to take place from Monday, February 12th, to Thursday, February 15th, 2024.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
PMI Q2 Call: ZYN Growth, IQOS Pricing and a Diverging Global Tobacco Market
Philip Morris International’s second-quarter earnings call offered new detail on its smoke-free strategy. Management said it would increase U.S. investment behind nicotine pouch brand ZYN, keep IQOS focused on volume before stronger pricing, and use SENTIA, DELIA, LEVIA, VEEV and ZYN to manage tax and regulatory pressure across Japan and Europe. Analysts from Goldman Sachs, Morgan Stanley, UBS and other firms also pressed PMI on profitability, market share, cigarette resilience and the durability of its global transformation over coming quarters.
Jul.24
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
InterTabac 2026: Further Sessions on Regulation, Market Access and Innovation Confirmed; 2FIRSTS to Host China Market Forum
InterTabac 2026: Further Sessions on Regulation, Market Access and Innovation Confirmed; 2FIRSTS to Host China Market Forum
InterTabac 2026 will bring together international experts to discuss European regulation, tax policy, Track & Trace, market access, retail impacts, consumer behavior and innovation. Sessions will also examine Poland’s tobacco-growing perspective and the growing fragmentation of Europe’s tobacco and nicotine market. Media partner 2FIRSTS will host the second “2FIRSTS Connect at InterTabac” on September 16, focusing on developments in China’s tobacco and nicotine industry.
Aug.06
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
UK HMRC Unveils Red and Yellow Transitional Vape Duty Stamps Ahead of October Tax Launch
HM Revenue & Customs (HMRC) has released sample images of the UK’s transitional vaping duty stamps, showing red and yellow versions ahead of the new Vaping Products Duty and Vaping Duty Stamps Scheme starting on October 1, 2026. Transitional stamps contain physical security features but no digital scanning function. Approved businesses may purchase them through November 30 and affix them through December 31. HMRC has not stated that the red and yellow samples represent different product categories or tax statuses.
Regulations
Sep.02